BioSpace News Archive

Merck Announces Effectiveness of the Form 10 Registration Statement for Organon

Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 40,000 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of an aggregate of 229,931 restricted stock units of Atara’s common stock to 47 newly hired employees and stock options to purchase an aggregate of 206,167 shares of Atara’s common stock to 15 such newly hired employees.

Flexion Therapeutics, Inc. announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 25,000 shares of the Company’s common stock with an exercise price of $4.16 per share, the closing price of Assembly Bio’s common stock on May 3, 2021.

Rising prevalence of cardiovascular diseases and increased preference for minimal invasive procedures with higher success rate to drive the angioplasty balloons market growth

Leading pharmaceutical companies are investing extensively in research & development activities to improve clinical trial effeciency

The demand in the global clinical laboratory tests market is expected to increment at a healthy CAGR during the forecast period of 2017 to 2025, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, prevalence of target diseases, growing demand for early detection of chronic diseases, and the introduction of innovative solutions.